{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed+or+Refractory+%28r%2Fr%29+B-cell+Non-Hodgkin+Lymphoma+%28NHL%29&page=2",
    "query": {
      "condition": "Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 31,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed+or+Refractory+%28r%2Fr%29+B-cell+Non-Hodgkin+Lymphoma+%28NHL%29&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed+or+Refractory+%28r%2Fr%29+B-cell+Non-Hodgkin+Lymphoma+%28NHL%29&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-10T12:17:48.311Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06526793",
      "title": "Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "B-cell Non-Hodgkin Lymphoma",
        "Follicular Lymphoma (FL)",
        "Large B-Cell Lymphoma (LBCL)"
      ],
      "interventions": [
        {
          "name": "Surovatamig",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 270,
      "start_date": "2024-11-27",
      "completion_date": "2032-10-21",
      "has_results": false,
      "last_update_posted_date": "2026-09-11",
      "last_synced_at": "2026-10-10T12:17:48.311Z",
      "location_count": 22,
      "location_summary": "Phoenix, Arizona • Duarte, California • Jacksonville, Florida + 19 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06526793"
    },
    {
      "nct_id": "NCT06104592",
      "title": "Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Large B-cell Lymphoma",
        "Relapsed Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Comprehensive Ablative Bridging Irradiation (CABI)",
          "type": "RADIATION"
        },
        {
          "name": "Chimeric Antigen Receptor T-Cell Therapy",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "BIOLOGICAL"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2023-11-08",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-03-31",
      "last_synced_at": "2026-10-10T12:17:48.311Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06104592"
    },
    {
      "nct_id": "NCT04305444",
      "title": "Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Relapsed Chronic Lymphocytic Leukemia",
        "Refractory Chronic Lymphocytic Leukemia",
        "Diffuse Large B Cell Lymphoma",
        "Follicular Lymphoma",
        "Richter's Transformation"
      ],
      "interventions": [
        {
          "name": "DTRM-555",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Zhejiang DTRM Biopharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "2020-04-24",
      "completion_date": "2024-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-01-08",
      "last_synced_at": "2026-10-10T12:17:48.311Z",
      "location_count": 8,
      "location_summary": "Phoenix, Arizona • New Haven, Connecticut • Jacksonville, Florida + 5 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04305444"
    },
    {
      "nct_id": "NCT04809467",
      "title": "A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia",
        "Non Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "tafasitamab",
          "type": "DRUG"
        },
        {
          "name": "parsaclisib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2021-09-16",
      "completion_date": "2024-10-22",
      "has_results": true,
      "last_update_posted_date": "2026-02-04",
      "last_synced_at": "2026-10-10T12:17:48.311Z",
      "location_count": 10,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Indianapolis, Indiana + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04809467"
    },
    {
      "nct_id": "NCT04526834",
      "title": "Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Anaplastic Large Cell Lymphoma",
        "Peripheral T Cell Lymphoma",
        "Extranodal NK/T-cell Lymphoma",
        "Diffuse Large B Cell Lymphoma",
        "Primary Mediastinal Large B-Cell Lymphoma (PMBCL)"
      ],
      "interventions": [
        {
          "name": "CD30.CAR-T",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tessa Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 21,
      "start_date": "2021-09-08",
      "completion_date": "2036-03",
      "has_results": false,
      "last_update_posted_date": "2023-04-20",
      "last_synced_at": "2026-10-10T12:17:48.311Z",
      "location_count": 4,
      "location_summary": "Duarte, California • Nashville, Tennessee • Houston, Texas",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04526834"
    },
    {
      "nct_id": "NCT02226965",
      "title": "PNT2258 for Treatment of Patients With r/r DLBCL (Wolverine)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma, Diffuse Large B-Cell"
      ],
      "interventions": [
        {
          "name": "PNT2258",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sierra Oncology LLC - a GSK company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2014-12",
      "completion_date": "2018-08-22",
      "has_results": true,
      "last_update_posted_date": "2023-06-29",
      "last_synced_at": "2026-10-10T12:17:48.311Z",
      "location_count": 26,
      "location_summary": "Long Beach, California • Los Angeles, California • Denver, Colorado + 22 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Winter Haven",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02226965"
    },
    {
      "nct_id": "NCT03610724",
      "title": "Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Tisagenlecleucel",
          "type": "BIOLOGICAL"
        },
        {
          "name": "lymphodepleting chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Bridging Therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "Up to 25 Years"
      },
      "enrollment_count": 34,
      "start_date": "2019-02-15",
      "completion_date": "2023-04-26",
      "has_results": true,
      "last_update_posted_date": "2024-06-20",
      "last_synced_at": "2026-10-10T12:17:48.311Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • San Francisco, California • Baltimore, Maryland + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03610724"
    },
    {
      "nct_id": "NCT06097364",
      "title": "A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Follicular Lymphoma (FL)"
      ],
      "interventions": [
        {
          "name": "Odronextamab",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        },
        {
          "name": "Prednisone/Prenisolone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 733,
      "start_date": "2023-11-14",
      "completion_date": "2029-07-29",
      "has_results": false,
      "last_update_posted_date": "2026-02-06",
      "last_synced_at": "2026-10-10T12:17:48.311Z",
      "location_count": 9,
      "location_summary": "Plantation, Florida • Noblesville, Indiana • Wichita, Kansas + 6 more",
      "locations": [
        {
          "city": "Plantation",
          "state": "Florida"
        },
        {
          "city": "Noblesville",
          "state": "Indiana"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06097364"
    },
    {
      "nct_id": "NCT05879744",
      "title": "A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "NHL",
        "NHL, Relapsed, Adult"
      ],
      "interventions": [
        {
          "name": "CLN-978",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cullinan Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 90,
      "start_date": "2023-05-31",
      "completion_date": "2027-04",
      "has_results": false,
      "last_update_posted_date": "2024-05-02",
      "last_synced_at": "2026-10-10T12:17:48.311Z",
      "location_count": 6,
      "location_summary": "Birmingham, Alabama • Duarte, California • Atlanta, Georgia + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05879744"
    },
    {
      "nct_id": "NCT06806033",
      "title": "Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma"
      ],
      "interventions": [
        {
          "name": "Obinutuzumab",
          "type": "DRUG"
        },
        {
          "name": "Glofitamab",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 130,
      "start_date": "2025-03-05",
      "completion_date": "2029-03-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-09",
      "last_synced_at": "2026-10-10T12:17:48.311Z",
      "location_count": 33,
      "location_summary": "Anchorage, Alaska • Clovis, California • Fullerton, California + 29 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Clovis",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06806033"
    }
  ]
}